Sight Sciences, Inc. announced the launch of the Ergo-Series of the OMNI Surgical System in Europe, a technology that facilitates surgeons' ability to perform minimally invasive, implant-free glaucoma procedures in adults with open-angle glaucoma. The Ergo-Series was originally launched in the United States in March 2023, and since has been broadly adopted by surgeon users of OMNI due to its improved ergonomics and an optimized cannula tip that provides gentle and precise access to Schlemm's canal.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.56 USD | +0.61% | +17.77% | +27.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.13% | 324M | |
-7.16% | 177B | |
-4.86% | 65.54B | |
-4.28% | 47.09B | |
+10.32% | 43.43B | |
+8.14% | 41.77B | |
+15.76% | 29.55B | |
+15.53% | 24.83B | |
-5.88% | 23.97B | |
-5.38% | 23.54B |
- Stock Market
- Equities
- SGHT Stock
- News Sight Sciences, Inc.
- Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting